Casimersen - Sarepta Therapeutics

Drug Profile

Casimersen - Sarepta Therapeutics

Alternative Names: SRP-4045

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sarepta Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Dystrophin expression modulators; Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy

Most Recent Events

  • 02 Aug 2018 Phase-III clinical trials in Duchenne muscular dystrophy (In adolescents, In children, In adults) in Italy, United Kingdom, Spain, USA (IV) (NCT03532542) (EudraCT2017-004625-32)
  • 24 Jun 2018 Biomarkers information updated
  • 22 May 2018 Sarepta Therapeutics plans a phase III extension trial for Duchenne muscular dystrophy in June 2018 (NCT03532542)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top